European Group for the Study of Resistant Depression (GSRD) - Where have we gone so far: Review of clinical and genetic findings

European Neuropsychopharmacology

Volumn 22, Issue 7, 2012, Pages 453-468

  Schosser, Alexandra ^a   Serretti, Alessandro ^b   Souery, Daniel ^c   Mendlewicz, Julien ^c   Zohar, Joseph ^e   Montgomery, Stuart ^d   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Affective disorders; Antidepressants; Depression; Genetics; Pharmacogenetics; Treatment resistance

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DYSBINDIN; KAINIC ACID RECEPTOR; LAMOTRIGINE; LITHIUM; PROSTAGLANDIN SYNTHASE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; VALPROIC ACID;

ANXIETY DISORDER; BIPOLAR DEPRESSION; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DNA POLYMORPHISM; DSM-IV; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PANIC; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REMISSION; RETROSPECTIVE STUDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PHOBIA; SUICIDAL BEHAVIOR; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EUROPE; GENETIC ASSOCIATION STUDIES; HUMANS; PHARMACOGENETICS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84861481592     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.02.006     Document Type: Review

References (124)

1. Arias B., Serretti A., Lorenzi C., Gasto C., Catalan R., Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord. 2006, 90:251-256.
2. Arias B., Serretti A., Mandelli L., Gasto C., Catalan R., Ronchi D.D., Fanasas L. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenet. Genomics 2009, 19:121-128.
3. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World. J. Biol. Psychiatry 2007, 8(2):67-104.
4. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., Deckert J., Arolt V., Domschke K. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008, 33:924-932.
5. Benson M.A., Newey S.E., Martin-Rendon E., Hawkes R., Blake D.J. Dysbindin, a novel coiled-coil-containing protein interacts with the dystrobrevins in muscle and brain. J. Biol. Chem. 2001, 276:24232-24241.
6. Berlim M.T., Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur. Neuropsychopharmacol. 2007, 17(11):696-707.
7. Berton O., Krishnan V., Nestler E.J. BDNF in anxiety and depression. Science 2006, 312:1598-1599.
8. Binder E.B., Holsboer F. Pharmacogenomics and antidepressant drugs. Ann. Med. 2006, 38:82-94.
9. Bishop J.R., Ellingrod V.L., Moline J., Miller D. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med. Sci. Monit. 2006, 12:BR47-BR50.
10. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol. Psychiatry 2006, 59:1144-1150.
11. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 2008, 11:1169-1180.
12. Bschor T., Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr. Scand. 2010, 121:174-179.
13. Chen L., Lawlor D.A., Lewis S.J., Yuan W., Abdollahi M.R., Timpson N.J., Day I.N., Ebrahim S., Smith G.D., Shugart Y.Y. Genetic association study of BDNF in depression: finding from two cohort studies and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147:814-821.
14. Cusin C., Serretti A., Lattuada E., Lilli R., Lorenzi C., Smeraldi E. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am. J. Med. Genet. 2002, 114:380-390.
15. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
16. Domschke K., Lawford B., Laje G., Berger K., Young R., Morris P., Deckert J., Arolt V., McMahon F.J., Baune B.T. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol. 2009, 23:1-9.
17. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
18. Emslie G.J., Mayes T.L., Laptook R.S., Batt M. Predictors of response to treatment in children and adolescents with mood disorders. Psychiatr. Clin. North Am. 2003, 26(2):435-456.
19. Fava M. Diagnosis and definition of treatment resistant depression. Biol. Psychiatry 2003, 53:649-659.
20. Fawcett J., Kravitz H.M. Treatment refractory depression. Common Treatment Problems in Depression 1985, American Psychiatric Press, Washington DC. A.F. Schatzberg (Ed.).
21. Fekadu A., Wooderson S., Donaldson C., Markopoulou K., Masterson B., Poon L., Cleare A.J. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J. Clin. Psychiatry 2009, 70(2):177-184.
22. Frisch A., Postilnick D., Rockah R., Michaelovsky E., Postilnick S., Birman E., Laor N., Rauchverger B., Kreinin A., Poyurosvsky M. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol. Psychiatry 1999, 4:389-392.
23. Funke B., Malhotra A.K., Finn C.T., Plocik A.M., Lake S.L., Lencz T., DeRosse P., Kane J.M., Kucherlapati R. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain Funct. 2005, 1:19.
24. Gaysina D., Cohen-Woods S., Chow P.C., Martucci L., Schosser A., Ball H.A., Tozzi F., Perry J., Muglia P., Craig I.W., McGuffin P., Farmer A. Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case-control study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150:836-844.
25. Gratacos M., Soria V., Urretavizcaya M., Gonzalez J.R., Crespo J.M., Bayés M., de Cid R., Menchón J.M., Vallejo J., Estivill X. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 2008, 8:101-112.
26. Grigoroiu-Serbanescu M., Martinez M., Nothen M.M., Grinberg M., Sima D., Propping P., Marinescu E., Hrestic M. Different familial transmission patterns in bipolar I disorder with onset before and after age 25. Am. J. Med. Genet. 2001, 105:765-773.
27. Guengerich F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21:70-83.
28. Halleland H., Lindervold A.J., Halmoy A., Haavik J., Johansson S. Association between catechol O-methyltransferase (COMT) haplotypes and severity of hyperactivity symptoms in adults. Am. J. Med. Genet. B 2009, 150:403-410.
29. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
30. Heimann H. Therapy-resistant depression: symptoms and syndromes. Contributions to symptomatology and syndromes. Pharmakopsychiatr. Neuropsychopharmakol. 1974, 7(3):139-144.
31. Hong C.J., Chen T.J., Yu Y.W., Tsai S.J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006, 6:27-33.
32. Horstmann S., Lucae S., Menke A., Hennings J.M., Ising M., Roeske D., Müller-Myhsok B., Holsboer F., Binder E.B. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010, 35:727-740.
33. Hosak L. Role of COMT gene Val158Met polymorphism in mental disorders: a review. Eur. Psychiatry 2007, 22:276-281.
34. Illi A., Setälä-Soikkeli E., Viiki M., Poutanen O., Huhtala H., Mononen N., Lehtimäki T., Leinonen E., Kampman O. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
35. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 2007, 116:496-526.
36. Ji Y., Biernacka J., Snyder K., Drews M., Pelleymounter L.L., Colby C., Wang L., Mrazek D.A., Winshilboum R.M. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics 2010, 28. (Epub ahead of print).
37. Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Miller A.L., Rogers G.R., Kennedy M.A. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int. J. Neuropsychopharmacol. 2003, 6:339-346.
38. Kang R.H., Hahn S.W., Choi M.J., Lee M.S. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 2007, 56:1-5.
39. Kato M., Wakeno M., Okugawa G., Fukuda T., Takekita Y., Hosoi Y., Azuma J., Kinoshita T., Serretti A. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1041-1044.
40. Keers R., Bonvicini C., Scassellati C., Uher R., Placentino A., Giovannini C., Rietschel M., Henigsberg N., Kozel D., Mors O., Maier W., Hauser J., Souery D., Mendlewicz J., Schmäl C., Zobel A., Larsen E.R., Szczepankiewicz A., Kovacic Z., Elkin A., Craig I., McGuffin P., Farmer A.E., Aitchison K.J., Gennarelli M. Variation in GNB3 predicts response and adverse reactions to antidepressants. J. Psychopharmacol. 2011, 25(7):867-874.
41. Kim J.J., Mandelli L., Pae C.U., Ronchi D.D., Jun T.Y., Lee C., Paik I.H., Patkar A.A., Steffens D., Serretti A., Han C. Is there a protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:375-379.
42. Kirchheiner J., Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 2007, 1770:489-494.
43. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., Noro M., Oswald P., Souery D., Zohar J., Massat I. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol. 2010, 25:218-227.
44. Kocabas N.A., Antonijevic I., Faghel C., Forray C., Kasper S., Lecrubier Y., Linotte S., Massat I., Montgomery S., Noro M., Oswald P., Snyder L., Souery D., Zohar J., Mendlewicz J. Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes. World J. Biol. Psychiatry 2010, 11:985-990.
45. Kocabas N.A., Antonijevic I., Faghel C., Forray C., Kasper S., Lecrubier Y., Linotte S., Massat I., Mendlewicz J., Noro M., Montgomery S., Oswald P., Snyder L., Zohar J., Souery D. Brain-derived neurotrophic factor (BDNF) gene polymorphisms: influence on treatment response phenotypes in major depressive disorder. Int. Clin. Psychopharmacol. 2011, 26:1-10.
46. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455:894-902.
47. Kunugi H., Vallada H.P., Hoda F., Kirov G., Gill M., Aitchison K.J., Ball D., Arranz M.J., Murray R.M., Collier D.A. No evidence for an association of affective disorders with high- or low-activity allele of catechol-O-methyltransferase gene. Biol. Psychiatry 1997, 42:282-285.
48. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
49. Lam R.W., Kennedy S.H., Grigoriadis S., McIntyre R.S., Milev R., Ramasubbu R., Parikh S.V., Patten S.B., Ravindran A.V. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinician guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 2009, 117(Suppl. 1):S26-S43.
50. Lee H.J., Cha J.H., Ham B.J., Han C.S., Kim Y.K., Lee S.H., Ryu S.H., Kang R.H., Choi M.J., Lee M.S. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 2004, 4:29-33.
51. Lehmann H.E. Therapy-resistant depression - a clinical classification. Pharmakopsychiatr. Neuropsychopharmakol. 1974, 7(3):156-163.
52. Lemonde S., Du L., Bakish D., Hrdina P., Albert P.R. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. Neuropsychopharmacol. 2004, 7:501-506.
53. Levin G.M., Bowles T.M., Ehret M.J., Langaee T., Tan J.Y., Johnson J.A., Millard W.J. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol. Diagn. Ther. 2007, 11:155-160.
54. Lin E., Chen P.S., Chang H.H., Gean P.W., Tsai H.C., Yang Y.K., Lu R.B. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1167-1172.
55. Massat I., Souery D., Del-Favero J., Nothen M., Blackwood D., Muir W., Kaneva R., Serretti A., Lorenzi C., Rietschel M., Milanova V., Papadimitriou G.N., Dikeos D., Van Broekhoven C., Mendlewicz J. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol. Psychiatry 2005, 10:598-605.
56. Massat I., Kocabas N.A., Crisafulli C., Chiesa A., Calati R., Linotte S., Kasper S., Fink M., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Serretti A., Mendlewicz J. COMT and age at onset in mood disorders: a replication and extension study. Neurosci. Lett. 2011, 498(3):218-221.
57. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., Rubert A., Tatarelli R., Nicoletti F., Girardi P., Shelton R.C. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J. Psychiatr. Res. 2009, 43:247-254.
58. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., Sorant A.J., Papanicolaou G.J., Laje G., Fava M., Trivedi M.H., Wisniewski S.R., Manji H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78:804-814.
59. Mendlewicz J., Massat I., Linotte S., Kasper S., Konstantinidis A., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Souery D., Group for the Study of Resistant Depression (GSRD) Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from a European Multicentre Study. Int. Clin. Psychopharmacol. 2010, 25(5):297-301.
60. Michaelovsky E., Gothelf D., Korostishevsky M., Frisch A., Burg M., Carmel M., Steinberg T., Inbar D., Apter A., Weizman A. Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. Int. J. Neuropsychopharmacol. 2007, 11:351-363.
61. Mier D., Kirsch P., Meyer-Lindenberg A.M. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry 2009, 1-10.
62. Neumeister A., Young T., Stastny J. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology 2004, 174(4):512-524. (Review).
63. NICE Clinical Guideline 23. 23, Depression: Management of Depression in Primary and Secondary Care 2007, 1-63. April 2007 (amended), National Institute for Clinical Excellence, London.
64. Nierenberg A.A., Keck P.E., Samson J. Methodological considerations for the study of treatment-resistant depression. Advances in Neuropsychiatry and Psychopharmacology: Refractory Depression 1991, 1-12. Raven Press, New York. J.D. Amsterdam (Ed.).
65. Noro M., Antonijevic I., Forray C., Kasper S., Kocabas N.A., Lecrubier Y., Linotte S., Mendlewicz J., Montgomery S., Snyder L., Souery D., Verbanck P., Zohar J., Massat I. 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int. Clin. Psychopharmacol. 2010, 25:228-231.
66. Ohara K., Nagai M., Suzuki Y., Ohara K. Low activity allele of catechol-O-methyltransferase gene and Japanese unipolar depression. Neuroreport 1998, 9:1305-1308.
67. Oquendo M.A., Malone K., Ellis S.P., Sackheim H.A., Mann J.J. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am. J. Psychiatry 1999, 156(2):190-194.
68. Oswald P., Del-Favero J., Massat I., Souery D., Claes S., Van Broeckhofen C., Mendlewicz J. No implication of brain-derived neurotrophic factor (BDNF) gene in unipolar affective disorder: evidence from Belgian first and replication patient-control studies. Eur. Neuropsychopharmacol. 2005, 5:491-495.
69. Paddock S., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., Lipsky R., Wisniewski S.R., Manji H., McMahon F.J. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am. J. Psychiatry 2007, 164:1181-1188.
70. Pae C.U., Serretti A., Mandelli L., Ronchi D.D., Patkar A.A., Jun T.Y., Kim J.J., Lee C.U., Lee S.J., Lee C., Paik I.H. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenet. Genomics 2007, 17:69-75.
71. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol. Psychiatry 2008, 63:699-704.
72. Parsey R.V., Olvet D.M., Oquendo M.A., Huang Y.Y., Ogden R.T., Mann J.J. Higher 5-HT(1A) receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 2006, 31:1745-1749.
73. Perlis R.H., Purcell S., Fagerness J., Cusin C., Yamaki L., Fava M., Smoller J.W. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol. Psychiatry 2007, 62:536-540.
74. Perlis R.H., Purcell S., Fava M., Fagerness J., Rush A.J., Trivedi M.H., Smoller J.W. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch. Gen. Psychiatry 2007, 64:689-697.
75. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol. Psychiatry 2009, 65:785-791.
76. Perlis R.H., Fijal B., Dharia S., Heinloth A.N., Houston J.P. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol. Psychiatry 2010, 67:1110-1113.
77. Peters E.J., Slager S.L., Kraft J.B., Jenkins G.D., Reinalda M.S., McGrath P.J., Hamilton S.P. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008, 3:e1872.
78. Posternak M.A., Zimmerman M. How accurate are patients in reporting their antidepressant treatment history?. J. Affect. Disord. 2003, 75:115-124.
79. Ruhé H.G., Huyser J., Swinkels J.A., Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J. Clin. Psychiatry 2006, 67(12):1836-1855.
80. Ruhé H.G., van Rooijen G., Spijker J., Peeters F.P., Schene A.H. Staging methods for treatment resistant depression. A systematic review. J. Affect. Disord. 2012, 137(1-3):35-45.
81. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackheim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163(11):1905-1917.
82. Rush A.J., Wisniewski S.R., Zisook S., Fava M., Sung S.C., Haley C.L., Chan H.N., Gilmer W.S., Warden D., Nierenberg A.A., Balasubramani G.K., Gaynes B.N., Trivedi M.H., Hollon S.D. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol. Med. 2011, 19:1-19. (Epub ahead of print).
83. Rybakowski J.K. BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008, 9:1589-1593.
84. Sackheim H.A., Prudic J., Devanand D.P., Decina P., Kerr B., Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J. Clin. Psychopharmacol. 1990, 10(2):96-104.
85. Schosser A., Kasper S. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int. Clin. Psychopharmacol. 2009, 24(6):277-288.
86. Schosser A., Calati R., Serretti A., Massat I., Kocabas N.A., Papageorgiou K., Linotte S., Mendlewicz J., Souery D., Zohar J., Juven-Wetzler A., Montgomery S., Kasper S. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder - a European Multicenter Study. Eur. Neuropsychopharmacol. 2012, 22(4):259-266.
87. Schumacher J., Jamra R.A., Becker T., Ohlraun S., Klopp N., Binder E.B., Schulze T.G., Deschner M., Schmäl C., Höfels S., Zobel A., Illig T., Propping P., Holsboer F., Rietschel M., Nöthen M.M., Cichon S. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol. Psychiatry 2008, 58:307-314.
88. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
89. Serretti A., Cusin C., Cristina S., Lorenzi C., Lilli R., Lattuada E., Grieco G., Costa A., Santorelli F., Barale F., Smeraldi E., Nappi G. Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatr. Genet. 2003, 13(2):121-126.
90. Serretti A., Lorenzi C., Cusin C., Zanardi R., Lattuada E., Rossini D., Lilli R., Pirovano A., Catalano M., Smeraldi E. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur. Neuropsychopharmacol. 2003, 13:117-122.
91. Serretti A., Artioli P., Lorenzi C., Pirovano A., Tubazio V., Zanardi R. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int. J. Neuropsychopharmacol. 2004, 7:453-460.
92. Serretti A., Calati R., Massat I., Linotte S., Kasper S., Lecrubier Y., Sens-Espel R., Bollen J., Zohar J., Berlo J., Lienard P., De Rochni D., Mendlewicz J., Souery D. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int. Clin. Psychopharmacol. 2009, 24:250-256.
93. Serretti A., Chiesa A., Calati R., Massat I., Linotte S., Kasper S., Lecrubier Y., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Mendlewicz J. A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. J. Affect. Disord. 2011, 128:56-63.
94. Serretti A., Chiesa A., Calati R., Massat I., Linotte S., Kasper S., Lecrubier Y., Fink M., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Mendlewicz J. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology. Psychiatry Res. 2011, 188(1):166-169.
95. Serretti A., Chiesa A., Crisafulli C., Massat I., Linotte S., Calati R., Kasper S., Bailer U., Lecrubier Y., Fink M., Antonijevic I., Forray C., Snyder L., Bollen J., Zohar J., De Ronchi D., Souery D., Mendlewicz J. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology 2012, 65(2):70-75.
96. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-23.
97. Sherbourne C., Schoenbaum M., Wells K.B., Croghan T.W. Characteristics, treatment patterns, and outcomes of persistent depression despite treatment in primary care. Gen. Hosp. Psychiatry 2004, 26(2):106-114.
98. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., Weinshilboum R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 2004, 9:151-160.
99. Shifman S., Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weizman A., Reznik I., Spivak B., Grisaru N., Karp L., Schiffer R., Kotler M., Strous R.D., Swartz-Vanetik M., Knobler H.Y., Shinar E., Beckmann J.S., Yakir B., Risch N., Zak N.B., Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 2002, 71:1296-1302.
100. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Whelan A., Cosyns P., de Jongh R., Maes M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 1998, 49:211-219.
101. Souery D., Van der Auwera K. The multiple facets of treatment resistant depression. CNS Spectr. 2004, 9(11):803-807.
102. Souery D., Amsterdam J., de Montigny C., Lecrubier Y., Montgomery S., Lipp O., Racagni G., Zohar J., Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 1999, 9(1-2):83-91.
103. Souery D., Papakostas G.I., Trivedi M.H. Treatment-resistant depression. J. Clin. Psychiatry 2006, 67(Suppl. 6):16-22.
104. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Mendlewicz J., Group for the Study of Resistant Depression Clinical factors associated with treatment resistance in major depression: results from a European Multicenter Study. J. Clin. Psychiatry 2007, 68(7):1062-1070.
105. Souery D., Serretti A., Calati R., Oswald P., Massat I., Konstantinidis A., Linotte S., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Zohar J., Mendlewicz J. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J. Clin. Psychopharmacol. 2011, 31(4):512-516.
106. Souery D., Serretti A., Calati A., Massat A., Konstantinidis A., Linotte S., Kasper S., Montgomery S., Zohar J., Mendlewicz J. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World. J. Biol. Psychiatry 2011, 12(5):364-375.
107. Souery D., Zaninotto L., Calati A., Linotte S., Sentissi O., Amital D., Moser U., Kasper S., Zohar J., Mendlewicz J., Serretti A. Phenomenology of psychotic mood disorders: lifetime and major depressive episode features. J. Affect. Disord. 2011, 135:241-250.
108. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokineti drug interactions with second-generation antidepressants: an update. Clin. Ther. 2008, 30:1206-1227.
109. Stassen H.H., Angst J., Hell D., Scharfetter C., Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J. Clin. Psychiatry 2007, 68(8):1195-1205.
110. Su K.P., Huang S.Y., Peng C.Y., Lai H.C., Huang C.L., Chen Y.C., Aitchison K.J., Pariante C.M. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol. Psychiatry 2010, 15:550-557.
111. Sulser F. The role of CREB and other transcription factors in the pharmacotherapy and etiology of depression. Ann. Med. 2002, 34:348-356.
112. Szegedi A., Rujescu D., Tadic A., Müller M.J., Kohnen R., Stassen H.H., Dahmen N. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005, 5:49-53.
113. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 1997, 58(Suppl. 13):23-29.
114. The European Agency for the Evaluation of Medicinal Products Evaluation of medicines for human use. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression 2002, April 25, European Agency for the Evaluation of Medicinal Products, London, England, CPMP/EWP/518/97, Rev.1. Available at:, Accessibility verified May 24, 2007. http://www.emea.europa.eu/pdfs/human/ewp/051897en.pdf.
115. Tsai S.J., Cheng C.Y., Yu Y.W., Chen T.J., Hong C.J. Association study of a brain-derived neurotrophic factor genetic polymorphism and major depressive disorder, symptomatology and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 123:19-22.
116. Wang J.W., Dranovsky A., Monckton J.E., Battaglia F., Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. 2008, 28:1374-1384.
117. Wilkie M.J., Smith D., Reid I.C., Day R.K., Matthews K., Wolf C.R., Blackwood D., Smith G. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics 2007, 17:207-215.
118. Wray N.R., James M.R., Handoko H.Y., Dumenil T., Lind P.A., Montgomery G.W., Martin N.G. Association study of candidate variants from a brain-derived neurotrophic factor and dystrobrevin-binding protein 1 with neuroticism, anxiety and depression. Psychiatr. Genet. 2008, 18:219-225.
119. Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su T.P., Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor induced signaling for glutamate release. J. Biol. Chem. 2006, 281:12941-12949.
120. Zill P., Baghai T.C., Zwanzger P., Schule C., Minov C., Riedel M., Neumeier K., Rupprecht R., Bondy B. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000, 11:1893-1897.
121. Zill P., Baghai T.C., Engel R., Zwanzger P., Schule C., Eser D., Behrens S., Rupprecht R., Möller H.J., Ackenheil M., Bondy B. The dysbindin gene in major depression: an association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 129:55-58.
122. Zubenko G.S., Hughes H.B., Stiffler J.S., Zubenko W.N., Kaplan B.B. Genome survey for susceptibility loci for recurrent, early-onset major depression: results at 10 cM resolution. Am. J. Med. Genet. 2002, 114:413-422.
123. Zubenko G.S., Hughes I.H., Stiffler J.S., Zubenko W.N., Kaplan B.B. D2S2944 identifies a likely susceptibility locus for recurrent, early-onset, major depression in women. Mol. Psychiatry 2002, 7:460-467.
124. Zubenko G.S., Hughes H.B., Stiffler J.S., Brechbiel A., Zubenko W.N., Maher B.S., Marazita M.L. Sequence variations in CREB1 cosegregate with depressive disorders in women. Mol. Psychiatry 2003, 8:611-618.